Literature DB >> 6482686

Monoclonal gammopathy in chronic active hepatitis.

M Heer, H Joller-Jemelka, A Fontana, U Seefeld, M Schmid, R Ammann.   

Abstract

Immunoelectrophoresis was performed in 31 of 272 patients with chronic active hepatitis (CAH) because of an M-spike component (seven patients, 2.6%) or hypergammaglobulinemia (24 patients) revealing a monoclonal gammopathy (MG) in 11 patients. In addition, 50 randomly selected patients with CAH and no evidence for an M-spike component were tested by immunoelectrophoresis. In 13 patients (26%), an MG was found. The mean age of the 24 patients with MG was 57.4 years (range: 23-76). HBsAg was present in nine patients (37.5%), no HBV-marker was detected in ten patients (41.7%). The immunoglobulin class of MG was IgG in ten patients (41.7%), IgA in one patient (4.2%) and IgM in 11 patients (45.8%). In two patients, Bence Jones protein was found in either serum or urine. In only one patient was the MG associated with multiple myeloma, whereas none of the other 23 patients developed a malignant lymphoproliferative disease within the median observation period of 6 years. We conclude that there is an unexpectedly high prevalence of benign MG in patients with CAH.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6482686     DOI: 10.1111/j.1600-0676.1984.tb00935.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  2 in total

1.  Primary sclerosing cholangitis in association with multiple myeloma.

Authors:  Nasrollah Ahmadpour; Matthew Downey; Elizabeth Frauenhoffer; Thomas Riley; Ian R Schreibman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-08

2.  Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.

Authors:  Linda Morris Brown; Gloria Gridley; David Check; Ola Landgren
Journal:  Blood       Date:  2008-01-31       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.